Analyst Ratings for Ionis Pharmaceuticals (IONS) [Neutrals]
IONS Rating Summary
IONS Price Target Summary
- Highest: $70.00 (BMO Capital)
- Lowest: $26.00 (Goldman Sachs)
- Average: $47.53
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$47.53 (+21.1%)
* Over Last 12-Mos
Rating Score: 4.3 / 10
Percentile Rank: 39%
Avg. $ Target:
$47.53 (+21.1%)
* Over Last 12-Mos
Rating Score: 4.3 / 10
Percentile Rank: 39%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/10/2021 | UBS | Esther Rajavelu | Upgrade | Neutral (Sell) |
37.50 (33.00) |
36.54 (39.25) |
7.42% | Details |
| 3/1/2021 | Barclays » Updated 5/5/2022 |
Gena Wang | Upgrade | Equalweight (Underweight) |
36.00 (33.00) |
53.41 (39.25) |
-26.51% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
IONS Ratings News
- AutoZone (AZO), Ionis Pharmaceuticals (IONS), and Thermo Fisher Scientific (TMO) Added to Citi Focus List. Four Names Removed
- Citi Reiterates Sell Rating on Ionis Pharmaceuticals (IONS), 'Limited Detail Keeps Us Weary on Competitive Profile', PT $26
- Stifel on Ionis Pharmaceuticals (IONS): 'we expect eplontersen to increase Ionis' share within the TTR space'
- See More
